Prescription drugs are expensive to develop, and many intermediaries stand between patients and drug makers. Here’s where the money goes.
The post Drug Spending in the US: Where the Money Actually Goes appeared first on DrugPatentWatch – Make Better De…
Drug Spending in the US: Where the Money Actually Goes Read Post »
Businessman and investor Mark Cuban is probably best known as the owner of the Dallas Mavericks and as an investor on the reality television series Shark Tank. His business and…
The post Mark Cuban Unexpected Leader in Orphan Drug Development Reform ap…
Mark Cuban Unexpected Leader in Orphan Drug Development Reform Read Post »
Anticipate the Future Global biopharmaceutical markets face constant change. To remain competitive you need to anticipate what’s next. We understand and work together with you to help you make better…
The post Helping You Make Better Decisions: The Dru…
Helping You Make Better Decisions: The DrugPatentWatch Design Philosophy Read Post »
Partner With DrugPatentWatch Become a Data Integration Partner DrugPatentWatch’s Data Integration Program is for companies that want to better serve their clients by building an integration between their technology and…
The post Partner With DrugPatent…
The average time to market for a new drug is around 12 years, at a cost averaging $2.6 billion, according to 2014 research by Tufts University. And there’s no indication that…
The post How AI Is Already Changing Drug Development appeared first on DrugP…
By Nanette Moss, S.M., C.I.H., Senior Scientist and Project Executive with Environmental Health & Engineering, Inc. What is business continuity planning and why it is important? Emergencies may be infrequent…
The post Business Continuity and Resiliency…
Business Continuity and Resiliency Planning for Biomedical and Research Organizations Read Post »
In November 2018, the Government Accountability Office (GAO) released a report titled “FDA Could Improve Designation Review Consistency; Rare Disease Drug Development Challenges Continue.” It follows up on the FDA’s Orphan…
The post Key Findings from G…
Key Findings from GAO Report on Orphan Drug Approval Modernization Read Post »
This article was originally published by Nigel S. Clarke in World Patent Information Volume 54, Supplement, September 2018, Pages S4-S10 under a Creative Commons license Abstract Some aspects of patent searching are…
The post The basics of patent searc…
This article was originally published by Hao Zhong, Ging Chan, Yuanjia Hu, Hao Hu and Defang Ouyang in Pharmaceutics 2018, 10(4), 263 under a Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). Abstract :…
The po…
A Comprehensive Map of FDA-Approved Pharmaceutical Products Read Post »
This paper was originally published by Maxwell Robert Morgan, Owen Gwilym Roberts, and Aled Morgan Edwards in Wellcome Open Res 2018, 3:154 under a Creative Commons Attribution License Abstract M4K…
The post Ideation and implementation of an open scien…
Get new actionable insights and updates from BiotechBlog
